Loading clinical trials...
Loading clinical trials...
A Multi-Center, Open-Label, Randomized, Parallel-Group Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine in Early Intervention.
To evaluate the efficacy of early intervention (dosing within 2 hours of onset of the migraine attack) with eletriptan 40mg on mild versus moderate to severe pain intensity of migraine.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Chilliwack, British Columbia, Canada
Pfizer Investigational Site
Coquitlam, British Columbia, Canada
Pfizer Investigational Site
Langley, British Columbia, Canada
Pfizer Investigational Site
North Vancouver, British Columbia, Canada
Pfizer Investigational Site
Penticton, British Columbia, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Bathurst, New Brunswick, Canada
Pfizer Investigational Site
Moncton, New Brunswick, Canada
Pfizer Investigational Site
St. John's, Newfoundland and Labrador, Canada
Start Date
March 1, 2005
Completion Date
October 1, 2006
Last Updated
January 27, 2021
220
Estimated participants
eletriptan
DRUG
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
NCT06641466
NCT07018713
NCT04715685
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions